Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-136344

Published: 2020

Journal Articles

CD4 + T Cell Fate in Multiple Myeloma

Rachel Elizabeth Cooke, BSc, FRACP, FRCPA, MBBS, Jessica Chung, PhD, Sarah Gabriel, PhD, Hang Quach, MD FRACP, FRCPA, MBBS, Simon J. Harrison, MBBS, MRCP, FRCPath, FRACP, PhD, H. Miles Prince, MD FRACP, FRCPA, Rachel Koldej, PhD, David Ritchie, MBChB, PhD FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2018-99-117674

Published: 2018

Journal Articles

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Blood (2018) 132 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2018-99-112847

Published: 2018

Journal Articles

Germline TIM-3 Mutations Characterize Sub-Cutaneous Panniculitis T-Cell Lymphomas with Hemophagocytic Lymphohistiocytic Syndrome

Blood (2018) 132 (Supplement 1): 1569.

https://doi.org/10.1182/blood-2018-99-120297

Published: 2018

Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Philippe Moreau, MDPhD, Albert Oriol, MD, Jonathan L. Kaufman, MD, Heather Sutherland, MD, Marc Lalancette, MD FRCP, Hila Magen, MD, Shinsuke Iida, MD PhD, Jin Seok Kim, MD PhD, Miles Prince, MD FRACP, FRCPA, Tara Cochrane, Lisa O'Rourke, MSN, RN, Kaida Wu, Jordan M. Schecter, Nizar J. Bahlis, MD

Blood (2017) 130 (Supplement 1): 1883.

https://doi.org/10.1182/blood.V130.Suppl_1.1883.1883

Published: 2017

Journal Articles

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Constantine S. Tam, MD, Hang Quach, MBBS, MD, Andrew Nicol, Xavier Badoux, Hannah Rose, H. Miles Prince, MD FRACP, FRCPA, Michael F. Leahy, FRACP,FRCPath,FRCP, Richard Eek, MBCHB, Nicholas Wickham, FRCPA,FRACP,FRCPath, Sushrut S. Patil, FRACP, FRCPA, Jane Huang, MD, Xiaoping Zhang, MD PhD, Lai Wang, PhD, Eric Hedrick, MD, William Novotny, Ian W. Flinn, MD PhD

Blood (2017) 130 (Supplement 1): 1745.

https://doi.org/10.1182/blood.V130.Suppl_1.1745.1745

Published: 2017

Journal Articles

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Blood (2017) 130 (Supplement 1): 1509.

https://doi.org/10.1182/blood.V130.Suppl_1.1509.1509

Published: 2017

Journal Articles

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Youn H Kim, MD, Sean Whittaker, MB, ChB, FRCP, MD, Steven M Horwitz, MD, Madeleine Duvic, MD, Reinhard Dummer, MD, Julia J Scarisbrick, MBChB FRCP MD, Pietro Quaglino, MD, Pier Luigi Zinzani, MD PhD, Pascal Wolter, MD, Yinghui Wang, MS, Maria Corinna Palanca-Wessels, MD PhD, Erin Zagadailov, PharmD, MS, William L Trepicchio, PhD, Yi Liu, PhD, Meredith Little, MPH, H Miles Prince, MD

Blood (2016) 128 (22): 182.

https://doi.org/10.1182/blood.V128.22.182.182

Published: 2016

Journal Articles

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

Philippe Moreau, Jonathan L. Kaufman, MD, Heather J. Sutherland, MD PhD, Marc Lalancette, MDFRCP-C, Hila Magen, MD, Shinsuke Iida, MD PhD, Jin Seok Kim, Miles Prince, MD, Tara Cochrane, Nushmia Z Khokhar, Mary Guckert, Xiang Qin, Albert Oriol

Blood (2016) 128 (22): 489.

https://doi.org/10.1182/blood.V128.22.489.489

Published: 2016

Journal Articles

Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers

Paul J Neeson, BSc, PhD, Alexander James Davenport, BSC, MSc, Joseph A Trapani, Michael Kershaw, PhD, Ryan Cross, H. Miles Prince, MD PhD, Ricky W Johnstone, PhD, David Ritchie, MD PhD, Phil Darcy, Misty R Jenkins

Blood (2016) 128 (22): 814.

https://doi.org/10.1182/blood.V128.22.814.814

Published: 2016

Journal Articles

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

Hang Quach, MD, Simon Harrison, MD, Liam J. Fernyhough, MB, BS, BMedSci, Ross Alistair Henderson, PhD FRACP, FRCPA, Gillian Corbett, MDFRACP FRCPA, Peter Browett, MBChB, FRACP, FRCPA, Hilary Anne Blacklock, FRACP, Craig Underhill, MD, Paul Cannell, MD, Judith Trotman, MBChB, Emma Link, Linda Cowan, Jack S Li, Meletios A. Dimopoulos, H. Miles Prince, MD

Blood (2015) 126 (23): 4236.

https://doi.org/10.1182/blood.V126.23.4236.4236

Published: 2015

Journal Articles

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Madeleine Duvic, MD, Timothy M Kuzel, MD, Nam H. Dang, MD PhD, Miles Prince, MD FRACP, FRCPA, Tatyana Feldman, MD, Francine M. Foss, MD, Matthew Guo, PhD, Lone Harild Ottesen, MD PhD, Chean Eng Ooi, PhD, Youn H Kim, MD

Blood (2014) 124 (21): 3097.

https://doi.org/10.1182/blood.V124.21.3097.3097

Published: 2014

Journal Articles

Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML

Michael J. Dickinson, MBBS, FRACP, FRCPA, Kirsten Herbert, MD BSci(MD, FRACP, PhD, Caroline Sardjono, MDPhD, Thao Le, MDPhD, Diana Zannino, BSc, MSc, Colin Wood, John F Seymour, MBBS, FRACP, PhD, Melita Kenealy, MD, Miles Prince, MD FRACP, FRCPA

Blood (2014) 124 (21): 4657.

https://doi.org/10.1182/blood.V124.21.4657.4657

Published: 2014

Journal Articles

A Cutaneous Lymphoma International Consortium ‘CLIC’ study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging

Julia J Scarisbrick, MBhons ChB FRCP MD, Pietro Quaglino, Maarten Vermeer, Sean Whittaker, Gary S. Wood, MD, Madeleine Duvic, MD, Miles Prince, MD FRACP, FRCPA, Steven M. Horwitz, MD, Richard T. Hoppe, MD, Pierluigi Porcu, MD, Rudolf Stadler, MD, Felicity Evison, Youn H Kim, MD

Blood (2014) 124 (21): 1621.

https://doi.org/10.1182/blood.V124.21.1621.1621

Published: 2014

Journal Articles

Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

Andrei R. Shustov, MD, Bertrand Coiffier, MD, PhD, Steven M. Horwitz, MD, Lubomir Sokol, MD, Ph.D, Barbara Pro, MD, Tina Nielsen, MD, PhD, Julie Wolfson, MPH, Barbara E Balser, VMD, Robin Eisch, RN, Leslie Popplewell, MD, Miles Prince, MD, FRACP, FRCPA, Steven L. Allen, M.D., Richard Piekarz, MD, PhD, Susan E. Bates, MD

Blood (2013) 122 (21): 4385.

https://doi.org/10.1182/blood.V122.21.4385.4385

Published: 2013

Journal Articles

Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06–0002 Study Update

Bertrand Coiffier, MD, PhD, Barbara Pro, MD, Miles Prince, MD, FRACP, FRCPA, Francine M. Foss, MD, Lubomir Sokol, MD, Ph.D, Matthew Greenwood, MD, FRACP, FRCPA, Dolores Caballero, MD, Franck Morschhauser, MD, PhD, Martin Wilhelm, MD, Lauren Pinter-Brown, MD, Swaminathan Padmanabhan, MD, Andrei R. Shustov, MD, Tina Nielsen, MD, PhD, Jean Nichols, PhD, Julie Wolfson, MPH, Barbara E Balser, VMD, Steven M. Horwitz, MD

Blood (2012) 120 (21): 3641.

https://doi.org/10.1182/blood.V120.21.3641.3641

Published: 2012

Journal Articles

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Douglas E Joshua, MBBS, DPhil, Mark S Hertzberg, MD, PhD, Bradley Auguston, Andrew Spencer, MD, Noemi Horvath, MB, ChB, FRACP, FRCPA, John Bashford, MBBS, FRACP, FRCPA, Lynda J Campbell, Eleanor Ashurst, Jacquelyn Wade, Michael C. Copeman, DPhil, FRACP, Belinda E Butcher, BSc(Hons) MBiostat PhD, Miles Prince, MD, FRACP, FRCPA

Blood (2012) 120 (21): 4065.

https://doi.org/10.1182/blood.V120.21.4065.4065

Published: 2012

Journal Articles

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

Chan Y Cheah, MBBS, FRACP, FRCPA, Michael S Hofman, MBBS FRACP, Michael J. Dickinson, MBBS, FRACP, FRCPA, Andrew Wirth, MBBS, FRANZCR, David A Westerman, MBBS, FRACP, FRCPA, FFSc, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Max Wolf, MBBS, FRACP, FRCPA, Elchanan H. Januszewicz, MBBS FRACP FRCPA, Kirsten Herbert, MD, BSci(Med), FRACP, PhD, Miles Prince, MD, FRACP, FRCPA, Dennis A Carney, MBBS FRACP FRCPA, David Ritchie, MBBS, FRACP, FRCPA, PhD, Rodney Hicks, MB BS, MD, FRACP, John F Seymour, MB, BS, PhD, FRACP

Blood (2012) 120 (21): 2652.

https://doi.org/10.1182/blood.V120.21.2652.2652

Published: 2012

Journal Articles

A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,

Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Campbell Tiley, MBBS, FRACP, FRCPA, Ilona Cunningham, John Moore, Miles Prince, MD, FRACP, FRCPA, Paul Cannell, MBBS, FRCPA, FRACP, Steve Gibbons, FRCPA, FRACP, MB, CHB, Jill Tate, BSc, MSc, FFSc, Sanjoy Paul, PhD, MSc, Devinder S Gill, MD

Blood (2011) 118 (21): 3973.

https://doi.org/10.1182/blood.V118.21.3973.3973

Published: 2011

Journal Articles

The Pan Histone Deacetylase Inhibitor Panobinostat and the Iso-Selective Inhibitor Romidepsin Reduce Glycoprotein VI Expression and Inhibit Platelet Activation in Response to Collagen Related Peptide

Mark J Bishton, Miles Prince, MD, FRACP, FRCPA, Ricky W Johnstone, PhD, Simon J. Harrison, MBBS MRCP (uk) MRCPath (uk) PhD, Benjamin T. Kile, PhD

Blood (2011) 118 (21): 1154.

https://doi.org/10.1182/blood.V118.21.1154.1154

Published: 2011

NARROW

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

CD4 + T Cell Fate in Multiple Myeloma

Superior Clinical Benefit of Brentuximab Vedotin in Mycosis Fungoides Versus Physician's Choice Irrespective of CD30 Level or Large Cell Transformation Status in the Phase 3 ALCANZA Study

Germline TIM-3 Mutations Characterize Sub-Cutaneous Panniculitis T-Cell Lymphomas with Hemophagocytic Lymphohistiocytic Syndrome

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM) Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

BGB-3111 in Combination with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia and Follicular Lymphoma

Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL)

Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients with CD30-Expressing Cutaneous T Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): The Phase 3 Alcanza Study

Efficacy of Daratumumab, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone for Relapsed or Refractory Multiple Myeloma Among Patients with 1 to 3 Prior Lines of Therapy Based on Previous Treatment Exposure: Updated Analysis of Pollux

Bigger, Stronger, Faster: Chimeric Antigen Receptor T Cells Are Olympic Killers

Lower Dose Lenalidomide and Dexamethasone for Patients with Relapsed/Refractory Multiple Myeloma Who Are Aged 60 Years or over and/or at Risk of Myelosuppression: Final Analysis of the Revlite Trial and Matched Comparison to the MM009 and MM010 Trials

A Dose Finding Lead-in Study of E7777 (Diphtheria toxin fragment-Interleukin-2 Fusion Protein) in Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL)

Final Analysis of a Phase II Study of Intrapatient Dose-Escalation of Eltrombopag in Patients Receiving Azacitidine for Myelodysplasia/AML

A Cutaneous Lymphoma International Consortium ‘CLIC’ study of Prognostic Parameters in Advanced Stages of Mycosis Fungoides and Sezary Syndrome: Progress Towards Establishing a Prognostic Index to Augment Clinical Staging

Romidepsin Is Effective and Well-Tolerated In Patients ≥ 60 Years Old With Relapsed Or Refractory Peripheral T-Cell Lymphoma (PTCL): Analysis From Phase 2 Trials

Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06–0002 Study Update

Bortezomib-Based Induction Overcomes Effect of 1q Amplification On Response in Newly-Diagnosed Myeloma and Results in Similar 2 Year Event-Free Survival

Surveillance PET-CT Scanning Is Useful in the First 18 Months Following Completion of Therapy for Patients with Diffuse Large B-Cell Lymphoma with IPI≥3.

A Phase II Study of Risk-Adapted Intravenous Melphalan in Patients with AL Amyloidosis,

The Pan Histone Deacetylase Inhibitor Panobinostat and the Iso-Selective Inhibitor Romidepsin Reduce Glycoprotein VI Expression and Inhibit Platelet Activation in Response to Collagen Related Peptide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only